[ad_1]
Pharmaceutical companies are stepping on the gas. After Biontech and Pfizer and Moderna, AstraZeneca now reports promising interim results. A study in The Lancet Medical Journal found that the AstraZeneca vaccine is better tolerated in people over the age of 70.
The study looked at the immunogenicity and tolerability of the AstraZeneca vaccine. This means how well the body’s immune response to the vaccine is. The immune response is equally good in all age groups. But the tolerance of the vaccine is better in older people. This is unusual because the immune response of particularly vulnerable people is often weaker.
Biontech and Pfizer are more
Analysis of the effectiveness of the vaccine is not expected in the next few weeks. But the first data can be expected for Christmas. Therefore, AstraZeneca is still one step behind Moderna and Biontech and Pfizer. Both reported good interim efficacy results. Biontech and Pfizer were even able to complete the third phase of the clinical study this week.
AstraZeneca is currently in this third phase of the clinical trial. The vaccine is tested on a large number of test subjects. After the study was temporarily stopped, the AstraZeneca experiments were resumed.
